(Q37683786)

22 August 2017

1 reference

title

Acute renal failure under dasatinib therapy (English)

1 reference

22 August 2017

main subject

dasatinib monohydrate

1 reference

1 reference

Sultan Ozkurt

1

1 reference

22 August 2017

Gokhan Temiz

series ordinal

2

1 reference

22 August 2017

Mustafa Fuat Acikalin

series ordinal

3

1 reference

22 August 2017

Mehmet Soydan

series ordinal

4

1 reference

22 August 2017

publication date

1 January 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

32

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

147-149

1 reference

Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

New dosing schedules of dasatinib for CML and adverse event management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903391226

10.3109/08860220903391226

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference